Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. Alexion Pharmaceuticals ( ALXN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.2%. By the end of trading, Alexion Pharmaceuticals fell 98 cents (-1.1%) to $91.37 on light volume. Throughout the day, 1.1 million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock ranged in price between $91.32-$93.06 after having opened the day at $92.80 as compared to the previous trading day's close of $92.35. Other companies within the Drugs industry that declined today were: ZIOPHARM Oncology ( ZIOP), down 64.5%, CEL-SCI Corporation ( CVM), down 12.6%, Novogen ( NVGN), down 9.8%, and Omeros Corporation ( OMER), down 9.1%.
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $18.25 billion and is part of the health care sector. The company has a P/E ratio of 73, above the S&P 500 P/E ratio of 17.7. Shares are down 1.5% year to date as of the close of trading on Monday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold. TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.